AIM ImmunoTech (NYSE: AIM) furnishes notices on Class E and F warrant changes

Rhea-AI Filing Summary

AIM ImmunoTech Inc. filed a current report describing that it has furnished to warrant holders two notices dated January 20, 2026, detailing changes and modifications to its Class E and Class F Common Stock Purchase Warrants. These notices, included as Exhibits 99.1 and 99.2, outline revised terms for those existing warrants but are provided for information purposes under Regulation FD and are not deemed filed under securities laws. The company also reiterates standard forward-looking statement cautions and emphasizes that further clinical testing is required to determine the effectiveness of its product candidate Ampligen® across various conditions.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0000946644 0000946644 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 20, 2026

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

Delaware		001-27072		52-0845822
(state or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

2117 SW Highway 484, Ocala FL		34473
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (352) 448-7797

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AIM		NYSE American

Item 7.01. Regulation FD Disclosure.

Furnished herewith as Exhibits 99.1 and 99.2, respectively, are a January 20, 2026 Notice of Change and Modifications of Class E Common Stock Purchase Warrants and a January 20, 2026 Notice of Change and Modifications of Class F Common Stock Purchase Warrants that were sent to the holders of these warrants.

The information, including Exhibits 99.1 and 99.2 referenced herein, are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference in such filing.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements included in the notices filed herewith may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the notices speak only as of the date of the notices. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date thereof. We are in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in our reports filed with the Securities and Exchange Commission (“SEC”) on our website and in our press releases set forth our current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in our reports filed with the SEC, on our website and in our press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in our latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. Our filings are available at www.aimimmuno.com. The information found on our website is not incorporated by reference herein and is included for reference purposes only.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed herewith:

Exhibit
Number		Description
99.1		“January 20, 2026 Notice of Change and Modifications of Class E Common Stock Purchase Warrants”
99.2		“January 20, 2026 Notice of Change and Modifications of Class F Common Stock Purchase Warrants”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AIM ImmunoTech Inc.
Date: January 20, 2026	By	/s/ Thomas K. Equels
		Thomas K. Equels, CEO

FAQ

What did AIM (AIM) disclose in this 8-K filing?

AIM ImmunoTech Inc. disclosed that it sent January 20, 2026 notices to holders of its Class E and Class F Common Stock Purchase Warrants explaining changes and modifications to those warrants, and furnished these notices as Exhibits 99.1 and 99.2.

Are the changes to AIM (AIM) Class E and F warrants fully described in this 8-K?

The 8-K states that notices of change and modifications for Class E and Class F Common Stock Purchase Warrants are furnished as Exhibits 99.1 and 99.2, but the specific warrant terms are contained in those exhibits rather than in the main text.

Does AIM ImmunoTech receive any proceeds or report new financing in this 8-K?

The filing describes notices of changes to existing Class E and Class F Common Stock Purchase Warrants and does not describe new financings, proceeds, or other major transactions in the main text.

How is the warrant modification information treated under securities laws in this AIM (AIM) filing?

The company states that the information, including Exhibits 99.1 and 99.2, is being "furnished" under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 unless later specifically incorporated by reference.

What forward-looking statement cautions does AIM (AIM) highlight here?

AIM notes that some statements in the notices may be forward-looking, invokes the Private Securities Litigation Reform Act safe harbor, and explains that extensive additional testing and clinical trials are required to determine whether Ampligen® will be effective for various diseases.

Where can investors find more risk information about AIM ImmunoTech (AIM)?

The company directs readers to the "Risk Factors" section in its latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are available on its website at www.aimimmuno.com and in its SEC filings.